Myasthenia Gravis Market Size, Share, And Growth Report 2032

Myasthenia Gravis Market Size

The global myasthenia gravis market size was worth around USD 1460.84 million in 2023 and is predicted to grow to around USD 2848.03 million by 2032 with a compound annual growth rate (CAGR) of roughly 7.7% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD million). The report covers a forecast and an analysis of the Myasthenia Gravis market on a global and regional level.

Request Free Sample

Myasthenia Gravis Market: Overview

Myasthenia Gravis is an autoimmune neuromuscular disorder that leads to serious muscle weakness. It is caused due to an error in the transmission of nerve impulses to muscles. It generally occurs when the normal communication between nerve and muscle disrupts at the neuromuscular joints. In this disorder, the antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint, which, in turn, prevents the muscles from contracting and performing normal functions. There is no permanent cure for this condition and it affects one’s quality of life.

The treatment helps in the improvement of the quality of life and life expectancy remains normal. The skeletal muscle weakness leads to the drooping eyelids, double vision, trouble in talking, walking trouble, etc. It mostly affects the eyes and facial muscles along with the gastrointestinal tract. The enlargement of the thymus or the development of thymoma can also be observed in myasthenia gravis patients. It can be diagnosed with the help of a blood test, nerve conduction test, and edrophonium test. Its treatment option includes the removal of thymus gland and medications, such as acetylcholinesterase inhibitors, immunosuppressant, etc.

As per the Myasthenia Gravis Foundation of America 2015, there were around 14 to 20 myasthenia gravis cases per 100,000 people, approximating nearly 36,000 to 60,000 cases of myasthenia gravis in the U.S. Furthermore, an increase in the number of autoimmune disorders coupled with strong product pipeline is also expected to drive the growth of the global myasthenia gravis market over the estimated period. The increase in healthcare expenditure, robust healthcare infrastructure, and growth in the awareness about the ailment among people is also anticipated to drive the growth of the global myasthenia gravis market.

Moreover, increased adoption of novel therapies along with favorable reimbursement policies in developed economies will promote the myasthenia gravis market globally. Increased research and development activities and massive investments are expected to create new growth opportunities in the myasthenia gravis market. However, the high treatment costs, limited availability of FDA-approved drugs may inhibit the growth of the myasthenia gravis market in the future.

Request Free Sample

Myasthenia Gravis Market: Segmentation

The study provides a decisive view of the myasthenia gravis market based on diagnosis, treatment, end-user, and region. All the segments have been analyzed based on present and future trends in the market are estimated from 2024 to 2032.

By diagnosis, the market is segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. Blood tests are expected to hold the major market share.

By treatment, the market is segmented into surgery, medication, plasmapheresis and intravenous immunoglobulin, autologous hematopoietic stem cell transplantation (HSCT), and others. The medication segment is expected to contribute majorly toward the global market over the forecast timespan.

By end-user, the market is segmented into hospitals, academic research institutes, clinics, and others. Hospitals are expected to hold the major market share in the future.

Myasthenia Gravis Market: Report Scope

Myasthenia Gravis Market: Regional Analysis

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Canada, Germany, France, UK, Brazil, China, Japan, India, and Brazil.

North America is expected to lead the global myasthenia gravis market over the forecast time period due to the increased adoption of novel therapies, increase in awareness among the people, favorable reimbursement policies, the presence of developed countries, such as the U.S. and Canada, and robust healthcare infrastructure. Europe is expected to be the second largest market over the forecast time period and closely follow North America in terms of revenue. Asia Pacific is expected to grow rapidly over the forecast time period, owing to the presence of developing economies such, as India and China, the presence of strong healthcare infrastructure, increased affordability, and substantial technological advancements.

Myasthenia Gravis Market: Competitive Players

Some key players of the global myasthenia gravis market are:

• Novartis Pharmaceuticals Corporation
• AbbVie Inc.
• Biogen Inc.
• Pfizer
• Valeant Pharmaceuticals International
• Bristol-Myers Squibb Company
• F. Hoffmann Roche La Ltd.
• GlaxoSmithKline
• RPG Life Sciences
• Grifols SA

The Global Myasthenia Gravis Market is segmented as follows:

Global Myasthenia Gravis Market: Diagnosis Analysis

• Edrophonium Tests
• Blood Tests
• Pulmonary Function Tests
• Electrodiagnostic
• Imaging
• Others

Global Myasthenia Gravis Market: Treatment Analysis

• Surgery
• Medication
• Plasmapheresis and Intravenous Immunoglobulin
• Autologous Hematopoietic Stem Cell Transplantation (HSCT)
• Others

Global Myasthenia Gravis Market: End-User Analysis

• Hospitals
• Academic Research Institutes
• Clinics
• Other

Global Myasthenia Gravis Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa